Galmed Pharmaceuticals Ltd.
The research page contains a warning that has not been mapped to a supported model interpretation. The company research remains available, but the complete score is withheld until the warning is reviewed.
GLMD · Price history
Price at last available close
$3.45
−$0.18 (-4.96%) 1M
2026-10-05
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Company & revenue
About Galmed Pharmaceuticals Ltd.
Primary reporting period: 2025-12-31 · Research updated Oct 13, 2026. A research update is not a new financial filing.
Who they are
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.
How they make money
Galmed Pharmaceuticals is a clinical-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity offerings and strategic financing to fund the research and development of its lead drug candidate, Aramchol, for liver, cardiometabolic, and GI oncological indications.
Products & services
The company is focused on the development of Aramchol, a synthetic fatty acid/bile acid conjugate, for the treatment of various liver, cardiometabolic, and GI oncological diseases.
Brands & revenue mix
Lead drug candidate for liver and cardiometabolic diseases.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Product / operating segments
No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
Customer types
Customer categories were not separately identified in the reviewed source set.
Customer concentration
No quantified customer-concentration disclosure is available in the current saved research.
Suppliers, materials & equipment
- Contract Research Organizations (CROs) — The company engages various third-party CROs to conduct clinical trials and provide research services; specific supplier names are not disclosed.Source
- Contract Manufacturing Organizations (CMOs) — The company relies on third-party manufacturers for the production of its drug candidates; specific supplier names are not disclosed.Source
Competitors
- Pharmaceutical and biotechnology companies — The company competes with various entities developing therapies for NASH, fibrosis, and other liver or cardiometabolic diseases, though specific competitors are not named in the filing.Source
Strengths
- Proprietary development of AramcholSource
Sources
Company-specific research
Questions worth answering for GLMD
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •How long can GLMD fund negative free cash flow using its current cash position before it may need more debt or new shares?
- •How is GLMD likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •What specifically needs to improve for GLMD to reach sustainable profitability?
- •What future growth or profitability would be needed to justify GLMD's current valuation?
- •What does the current fundamental change risk warning mean for the reliability or interpretation of GLMD's score?
Essential Investment Snapshot
Market Cap
$4.8M
P/E Ratio
-0.3
EPS
$-13.82
52-Week High
$13.20
52-Week Low
$3.29
Beta
0.67
Shares Outstanding
539K
Total Debt
$129K
Dividend
No current dividend
Liquidation Value / Share
$23.64
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Strong downward momentum
Extreme movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Community Sentiment
0 active · 0 total callsNo personal call yet on GLMD.
Potential upside factors
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Proprietary development of Aramchol.
Potential downside factors
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
- −Going concern uncertainty due to recurring losses and limited capital.
- −Dependence on clinical trial success and regulatory approval.
- −Diluted weighted-average shares increased 92.9% year over year.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
Score changes will appear once more historical records are available.
Price vs. Value
Valuation unavailableCurrent Price
$4.63
Model Intrinsic Value
—
Difference
—
Margin of Safety
—
Intrinsic value is not currently available for this stock, so valuation can't be calculated.
Financial Charts
Revenue
Additional Metrics
Operating Cash Flow
Total Debt
Total Assets
Net Margin %
Large reported revenue change: +87.8%
Revenue changed sharply from 2017 to 2018. This can reflect a real business change, acquisition, divestiture, discontinued operations, restatement, or reporting-basis change. Compare the underlying filing before treating it as normal growth or decline.
TTM may combine quarters from before and after the event, so its trend can also be distorted.
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
| Line Item | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cost of Revenue | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Gross Profit | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Research & Development | — | $4.9M | $3.0M | $3.6M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| SG&A Expenses | — | $3.6M | $3.3M | $3.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Expenses | — | $8.5M | $6.3M | $7.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| EBITDA | — | -$10.3M | -$7.4M | -$6.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating Income | — | -$8.5M | -$6.3M | -$7.5M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Interest Expense | — | $0.00 | $15K | $11K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Before Tax | — | -$10.3M | -$7.5M | -$6.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Income Tax Expense | — | $0.00 | $0.00 | $0.00 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Net Income | — | -$10.3M | -$7.5M | -$6.9M | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic EPS | — | $-19.12 | $-64.64 | $-240.40 | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Basic Shares | 952K | 539K | 116K | 28.8K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Diluted Shares | 952K | 539K | 116K | 28.8K | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
Earnings Summary
Revenue
$0
Estimate unavailable.
Revenue Beat/Miss
Not available (no estimate stored)
EPS
-$2.86
Estimate unavailable.
EPS Beat/Miss
Not available (no estimate stored)
Debt Change
Not available
Cash Change
-38.7%
Margin Change
Not available
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Weakened
- Cash position declined
Potential Score Impact
Pressure indicators included EPS growth, cash levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
EPS declined 43.3%. Cash declined 38.7%.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Insider Activity
Guru / Smart Money
Guru Score
Smart Money
Number of Gurus
Total Guru Value
Avg Portfolio Weight
Largest Holder
Largest Holder %
New Positions
Increased Positions
Reduced Positions
Exited Positions
Net Guru Sentiment
Short Interest
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Conservative Projected Values
3 Years
$———.——
5 Years
$———.——
10 Years
$———.——
Conservative Projection Rate
——%
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Start 7-Day Free TrialHistorical Outperformance Record
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.
Start 7-Day Free TrialHistorical Trends
5 historical recordsHistorical Score Chart
3 of 5 records shownWall Street Score
Debt Score
Revenue Score
Asset Score
Capital Score
Management Score
Moat Score
Valuation Score
Buffett Score
Intrinsic Value
Value Reference
Margin of Safety %
Related Companies
BiotechnologyNews
Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
Rumor Mill · GLMD
Corporate developments & opportunities
No reviewed developments match this filter.
Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial